8-K: Revvity Announces Strong Q1 2025 Financial Results, Reaffirming Full-Year Guidance

Revvity reports a solid first quarter with revenue of $665 million and reaffirms its full-year 2025 guidance for organic growth and adjusted EPS.

Summary

• Revvity, Inc. reported its financial results for the first quarter ended March 30, 2025.
• Revenue for the quarter was $665 million, a 2% increase compared to $650 million in the same period last year, with 4% organic growth.
• GAAP earnings per share (EPS) were $0.35, up from $0.21 in the same period a year ago.
• Adjusted EPS from continuing operations was $1.01, compared to $0.98 in the same period last year.
• The company's GAAP operating income from continuing operations was $72 million, compared to $44 million for the same period a year ago.
• The GAAP operating profit margin from continuing operations was 10.9%, compared to 6.8% in the same period a year ago.
• Adjusted operating income was $170 million, compared to $166 million for the same period a year ago.
• Adjusted operating profit margin was 25.6%, compared to 25.5% in the same period a year ago.
• For the full year 2025, Revvity is raising its revenue guidance to a range of $2.83-$2.87 billion.
• The company is reaffirming its organic growth guidance of 3-5% and adjusted EPS guidance of $4.90-$5.00 for the full year 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong Q1 results, increased revenue guidance, and reaffirmed full-year expectations. While there are inherent risks, the overall tone is optimistic and indicates confidence in the company's performance.

Positives

• Revvity reported a 2% increase in revenue, reaching $665 million in Q1 2025.
• The company experienced 4% organic revenue growth in Q1 2025.
• GAAP EPS increased from $0.21 to $0.35 year-over-year.
• Adjusted EPS from continuing operations increased from $0.98 to $1.01 year-over-year.
• GAAP operating income from continuing operations increased from $44 million to $72 million year-over-year.
• The company is raising its full-year 2025 revenue guidance to $2.83-$2.87 billion.
• Life Sciences adjusted operating income increased to $106 million, with an adjusted operating profit margin of 31.1%.
• Diagnostics revenue increased 3% to $324 million.

Negatives

• Diagnostics adjusted operating income decreased to $74 million, with an adjusted operating profit margin of 22.8%, compared to $76 million and 24.3% respectively in the same period a year ago.

Risks

• The press release contains forward-looking statements that are subject to various risks and uncertainties.
• These risks include market declines, economic and political fluctuations, failure to introduce new products, and the ability to execute acquisitions and divestitures.
• Other risks include competition, disruptions in supply chains, loss of key personnel, IT system disruptions, and failure to protect intellectual property.
• The company also faces risks related to government regulations, data privacy, healthcare industry regulations, and foreign operations.
• Fluctuations in the stock price and restrictions in credit agreements are also potential risks.

Future Outlook

Revvity is raising its full-year 2025 revenue guidance to a range of $2.83-$2.87 billion and reaffirming its organic growth guidance of 3-5% and adjusted EPS guidance of $4.90-$5.00.

Management Comments

• Prahlad Singh, president and chief executive officer of Revvity, stated that the company navigated a dynamic environment and delivered strong first quarter results.
• Singh noted that strong execution and the uniqueness of their businesses drove revenue, earnings, and cash flow to exceed expectations.
• He added that the first quarter performance positions them well for the remainder of the year as they continue to adapt to an evolving macroeconomic backdrop.

Industry Context

Revvity's focus on health science solutions, including translational multi-omics technologies and diagnostics, aligns with the growing demand for personalized medicine and advanced healthcare technologies. The company's performance reflects its ability to capitalize on these trends in the pharmaceutical, biotech, and diagnostic sectors.

Comparison to Industry Standards

• Comparing Revvity's organic growth of 4% with companies like Danaher (historically around 5-7% organic growth) and Thermo Fisher Scientific (around 6-8% organic growth) suggests Revvity is performing competitively but has room for improvement.
• Revvity's adjusted operating margin of 25.6% is comparable to that of Agilent Technologies, which often reports operating margins in the range of 22-27%.
• In the diagnostics segment, companies like Roche and Abbott often see revenue growth in the low to mid-single digits, making Revvity's 3% revenue increase in this segment competitive.
• Revvity's Life Sciences segment's 2% organic revenue growth is lower than that of some specialized life science companies like Bio-Rad Laboratories, which can see growth rates in the mid-single digits depending on market conditions.

Stakeholder Impact

• Shareholders can expect continued growth and profitability, as indicated by the raised revenue guidance and reaffirmed EPS guidance.
• Employees can anticipate stability and potential opportunities for advancement within a growing company.
• Customers will benefit from Revvity's continued investment in innovative health science solutions.
• Suppliers can expect continued business relationships with a financially stable company.
• Creditors can be confident in Revvity's ability to meet its financial obligations.

Next Steps

• The company will discuss its first quarter 2025 results and its outlook for business trends during a webcast on April 28, 2025, at 8:00 a.m. Eastern Time.

Key Dates

Keywords

financial results, Revvity, earnings, revenue, EPS, guidance, organic growth, diagnostics, life sciences